Release operational capacity
Estimate time that coordinated digital workflows could return to care and program teams.
Value estimator
See the value before you commit
Model linked digital uptake, administrative capacity and recovered follow-ups. Compare local economics and qualified global study evidence without signing up.
Three steps to a defensible business case
- 01
Set your scale
Choose your organisation type and annual patient volume.
- 02
Compare linked models
Review cohort assumptions, scenarios and optional local economics.
- 03
Take it to the room
Print a personalised summary for your leadership or budget review.
Build the business case
See where connected care could create operational value.
Start with the workflows that consume time today, then model a directional opportunity using your own operating inputs.
Recover follow-up opportunities
Explore the potential effect of structured reminders and follow-up on missed interactions.
Create a unified view
Model how many patients could move through one trackable digital workflow.
Your modelled opportunity
Directional opportunity
- Remaining capacity
- 4,050
- Follow-up recovery
- +900
- Digital reach
- 20,000
annual hours after recovered follow-up admin time
additional completed interactions annually
patients reached under the uptake assumption
From reach to capacity
80%
Digital reach
Workflow cohort
Annual patients25,000
Digitally reached patients20,000
Workflow-eligible reached patients14,000
Administrative capacityhours / year
Gross administrative hours released4,200
Admin hours used by recovered interactions150
Remaining released hours4,050
Illustrative estimates only. Actual outcomes vary by organization, workflow configuration, adoption and implementation scope.
The model also indicates up to SAR 384,750 in annual capacity value. This is not a savings forecast.
Linked annual model
Patients × uptake → eligible workflows × time reduction. Recovered follow-up time is deducted before valuing remaining capacity.
- Digitally reached patients
- 20,000
- Workflow-eligible reached patients
- 14,000
- Missed interactions in reached cohort
- 3,600
- Gross administrative hours released
- 4,200
- Admin hours used by recovered interactions
- 150
- Remaining released hours
- 4,050
Scenario comparison
| Scenario | Remaining hours | Recovered interactions |
|---|---|---|
| Conservative | 1,080 | 270 |
| Central | 4,050 | 900 |
| High-opportunity | 10,936.9 | 1,710 |
Scenario ranges are planning assumptions, not study confidence intervals. Custom assumptions apply to the selected scenario only.
Evidence & source boundaries
Evidence & source boundaries
Attendance risk ratio 1.14 versus no reminder; 7 trials, 5,841 participants in the SMS/no-reminder comparison.
International outpatient trials. A relative attendance increase, NOT a 14% reduction in missed appointments. Local applicability is unvalidated.
Mean PDC 64.8% versus 50.1% (+14.7 percentage points); 29.2% lower medical costs, excluding biologic/targeted drugs.
Sponsor-funded US observational adalimumab study; 2,268 matched patients. All-cause medical costs exclude biologic/targeted drugs; total cost including those drugs was not significantly lower (p=0.056). Associations, not causal effects. PDC is not the proportion of adherent patients. Supplied PSP report, pp. 4 & 7.
38% lower adjusted direct acute-episode cost in a US randomized trial of 91 adults.
Two-site, selected acute-care population; US costing and clinical selection do not transfer automatically to Saudi home healthcare. Comparator only, not a CareSync effect.
Supplied reports & cases
- The business case for connected digital care
GASTAT Health Status Statistics 2024, report p. 3: self-reported chronic disease among adults aged 15+. Population evidence, not CareSync outcomes.
- Navigating the future of connected care in Saudi Arabia
EY’s 2026 Saudi survey. Self-reported attitudes; external research, not CareSync outcomes.
- From program to platform
Brixner et al. (2019), report pp. 4 & 7: mean PDC 64.8% vs 50.1%; 29.2% lower medical costs excluding biologic/targeted drugs. Study-specific, not CareSync results. KSA scenario assumptions are unvalidated.
Saudi prevalence (18.95%, GASTAT 2024) and EY survey attitudes (89% trust; 88% willingness to share) are context only—not uptake, conversion or improvement rates. Brochures describe capabilities, not outcomes.
What we measure
Capacity released
Staff hours freed from manual coordination and follow-up.
Continuity of care
Additional completed follow-ups across patient journeys.
Digital reach
Patients actively engaged through your branded channels.
Estimates are illustrative and based on stated assumptions, not guaranteed outcomes.
Your personalized demo
Your care. Your brand. One platform.
See how CareSync brings your patients and teams together in a branded experience.
- Live demo
- Solution mapping
- Commercial proposal
Prefer to talk first?
Chat on WhatsApp